Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Combined meta-analysis of systemic effects of allogeneic stem cell transplantation and systemic sclerosis.

Grigoryev DN, Dalal J, Becker ML, Ye SQ.

BMC Hematol. 2014 Mar 22;14(1):7. doi: 10.1186/2052-1839-14-7.

2.

Extracorporeal photophoresis: an evidence-based analysis.

Health Quality Ontario..

Ont Health Technol Assess Ser. 2006;6(6):1-82.

3.

Gene expression profiling-based identification of CD28 and PI3K as new biomarkers for chronic graft-versus-host disease.

Lai P, Weng J, Lu Z, Guo R, Luo C, Wu S, Ling W, Geng S, Du X.

DNA Cell Biol. 2011 Dec;30(12):1019-25. doi: 10.1089/dna.2011.1284.

4.

Oral disease profiles in chronic graft versus host disease.

Bassim CW, Fassil H, Mays JW, Edwards D, Baird K, Steinberg SM, Cowen EW, Naik H, Datiles M, Stratton P, Gress RE, Pavletic SZ.

J Dent Res. 2015 Apr;94(4):547-54. doi: 10.1177/0022034515570942.

5.

Antibodies against human cytomegalovirus late protein UL94 in the pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host disease.

Pastano R, Dell'Agnola C, Bason C, Gigli F, Rabascio C, Puccetti A, Tinazzi E, Cetto G, Peccatori F, Martinelli G, Lunardi C.

Int Immunol. 2012 Sep;24(9):583-91. doi: 10.1093/intimm/dxs061.

PMID:
22773152
6.

Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease.

Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, Tedder TF, Fujimoto M.

Blood. 2013 Apr 18;121(16):3274-83. doi: 10.1182/blood-2012-11-465658.

7.

Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.

Apisarnthanarax N, Donato M, Körbling M, Couriel D, Gajewski J, Giralt S, Khouri I, Hosing C, Champlin R, Duvic M, Anderlini P.

Bone Marrow Transplant. 2003 Mar;31(6):459-65.

PMID:
12665841
8.

Clinical, serologic and instrumental data of ten patients affected by sclerodermatous chronic graft versus host disease: similarities and differences in respect to systemic sclerosis.

Barausse G, Caramaschi P, Scambi C, Benedetti F, Sorio M, Tinelli M, Tinazzi I, Benini L, Bambara LM, Biasi D.

Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):373-7.

PMID:
20378027
9.

Microchimerism and systemic sclerosis.

Scaletti C, Vultaggio A, Maggi E, Romagnani S, Piccinni MP.

Int Arch Allergy Immunol. 2001 Jul;125(3):196-202. Review.

PMID:
11490151
10.

Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.

Le Huu D, Kimura H, Date M, Hamaguchi Y, Hasegawa M, Hau KT, Fujimoto M, Takehara K, Matsushita T.

J Dermatol Sci. 2014 Jun;74(3):214-21. doi: 10.1016/j.jdermsci.2014.02.008.

PMID:
24679982
11.

Circulating endothelial progenitor cells decreased in patients with sclerodermatous chronic graft-versus-host disease.

Shimura K, Ashihara E, Shimazaki C, Matsunaga S, Taniguchi K, Uchiyama H, Matsumoto Y, Kimura S, Matsubara H, Taniwaki M, Maekawa T.

Biol Blood Marrow Transplant. 2008 Apr;14(4):426-37. doi: 10.1016/j.bbmt.2008.02.001.

12.

Meta-analysis of molecular response of kidney to ischemia reperfusion injury for the identification of new candidate genes.

Grigoryev DN, Cheranova DI, Heruth DP, Huang P, Zhang LQ, Rabb H, Ye SQ.

BMC Nephrol. 2013 Oct 24;14:231. doi: 10.1186/1471-2369-14-231.

13.

Transplantation of Donor-Origin Mouse Embryonic Stem Cell-Derived Thymic Epithelial Progenitors Prevents the Development of Chronic Graft-Versus-Host Disease in Mice.

Hu R, Liu Y, Su M, Song Y, Rood D, Lai L.

Stem Cells Transl Med. 2016 Aug 2. pii: sctm.2016-0012. [Epub ahead of print]

14.

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.

Grube M, Holler E, Weber D, Holler B, Herr W, Wolff D.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1781-91. doi: 10.1016/j.bbmt.2016.06.020.

PMID:
27343720
15.

Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.

Solomon SR, Sizemore CA, Ridgeway M, Zhang X, Smith J, Brown S, Holland HK, Morris LE, Bashey A.

Biol Blood Marrow Transplant. 2015 Sep;21(9):1576-82. doi: 10.1016/j.bbmt.2015.04.023.

16.

Phenotypical and functional characterization of bone marrow mesenchymal stem cells in patients with chronic graft-versus-host disease.

Wang B, Hu Y, Liu L, Hu K, Tie R, He Y, Fu S, Zhu N, Luo Y, Yu X, Huang H.

Biol Blood Marrow Transplant. 2015 Jun;21(6):1020-8. doi: 10.1016/j.bbmt.2015.02.013.

17.

Nailfold capillary abnormalities in sclerodermatous chronic GVHD.

Hofstee HM, de Waal TT, Zweegman S, Voskuyl AE, Smulders YM, Schoordijk MC, Janssen JJ, Serné EH.

Bone Marrow Transplant. 2013 Nov;48(12):1574-7. doi: 10.1038/bmt.2013.106.

PMID:
23892332
18.

The prevalence and prognostic value of concomitant eosinophilia in chronic graft-versus-host disease after allogeneic stem cell transplantation.

Mortensen KB, Gerds TA, Bjerrum OW, Lindmark A, Sengeløv H, Andersen CL.

Leuk Res. 2014 Mar;38(3):334-9. doi: 10.1016/j.leukres.2013.12.009.

PMID:
24439053
19.

Skin ulcers related to chronic graft-versus-host disease: clinical findings and associated morbidity.

Jachiet M, de Masson A, Peffault de Latour R, Rybojad M, Robin M, Bourhis JH, Xhaard A, Dhedin N, Sicre de Fontbrune F, Suarez F, Barete S, Parquet N, Nguyen S, Ades L, Rubio MT, Wittnebel S, Bagot M, Socié G, Bouaziz JD.

Br J Dermatol. 2014 Jul;171(1):63-8. doi: 10.1111/bjd.12828.

PMID:
24404963
20.

Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.

Hakim FT, Memon S, Jin P, Imanguli MM, Wang H, Rehman N, Yan XY, Rose J, Mays JW, Dhamala S, Kapoor V, Telford W, Dickinson J, Davis S, Halverson D, Naik HB, Baird K, Fowler D, Stroncek D, Cowen EW, Pavletic SZ, Gress RE.

J Immunol. 2016 Nov 1;197(9):3490-3503.

PMID:
27694491

Supplemental Content

Support Center